Cargando…

Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes

BACKGROUND: The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the anthracycline modification effects and to analyze reasons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liutkauskiene, Sigita, Grizas, Saulius, Jureniene, Kristina, Suipyte, Jorune, Statnickaite, Akvile, Juozaityte, Elona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910571/ https://www.ncbi.nlm.nih.gov/pubmed/29678165 http://dx.doi.org/10.1186/s12885-018-4365-y

Ejemplares similares

Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients
por: Liutkauskiene, Sigita, et al.
Publicado: (2015)

Prognostic Impact of Global Longitudinal Strain and NT-proBNP on Early Development of Cardiotoxicity in Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy
por: Muckiene, Gintare, et al.
Publicado: (2023)

The Impact of Polymorphisms in ATP-Binding Cassette Transporter Genes on Anthracycline-Induced Early Cardiotoxicity in Patients with Breast Cancer
por: Muckiene, Gintare, et al.
Publicado: (2023)

Systemic Optimization of Gene Electrotransfer Protocol Using Hard-to-Transfect UT-7 Cell Line as a Model
por: Vadeikienė, Roberta, et al.
Publicado: (2022)

Analysis of intracorporeal knotting with invaginating suture versus endoloops in appendiceal stump closure
por: Kiudelis, Mindaugas, et al.
Publicado: (2012)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients
por: Inciura, Arturas, et al.
Publicado: (2006)

Advances in anthracycline chemotherapy : epirubicin /
Publicado: (1984)

Anthracycline dose and liver dysfunction
por: Cannizzaro, R, et al.
Publicado: (1999)

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel
por: Fountzilas, George, et al.
Publicado: (2012)

Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective–prospective cohort multicentre study
por: Cesas, Alvydas, et al.
Publicado: (2023)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

Neutrophil-guided dosing of anthracycline–cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study
por: Drooger, Jan C., et al.
Publicado: (2015)

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
por: Castoldi, Francesca, et al.
Publicado: (2018)

RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy
por: Xia, Peng, et al.
Publicado: (2023)

Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience
por: Dambrauskiene, Ruta, et al.
Publicado: (2015)

Pathomorphological Manifestations and the Course of the Cervical Cancer Disease Determined by Variations in the TLR4 Gene
por: Žilienė, Eglė, et al.
Publicado: (2023)

Delayed Onset Anthracycline-Associated Cardiotoxicity Presenting as Acute Decompensated Heart Failure Seven Years After Chemotherapy Completion
por: Tran, Dan B, et al.
Publicado: (2021)

Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers
por: Lee, Hee Jin, et al.
Publicado: (2015)

Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients With Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment
por: Wonders, Karen Y., et al.
Publicado: (2023)

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval
por: Iqbal, Mohammad, et al.
Publicado: (2020)

Nonprehensile Manipulation of Parts on a Horizontal Circularly Oscillating Platform with Dynamic Dry Friction Control
por: Kilikevičius, Sigitas, et al.
Publicado: (2021)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy
por: Shima, Hiroaki, et al.
Publicado: (2022)

siRNA Knockdown of REDD1 Facilitates Aspirin-Mediated Dephosphorylation of mTORC1 Target 4E-BP1 in MDA-MB-468 Human Breast Cancer Cell Line
por: Savukaitytė, Aistė, et al.
Publicado: (2021)

DDIT4 Downregulation by siRNA Approach Increases the Activity of Proteins Regulating Fatty Acid Metabolism upon Aspirin Treatment in Human Breast Cancer Cells
por: Savukaitytė, Aistė, et al.
Publicado: (2023)

Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
por: Kim, Jung Sun, et al.
Publicado: (2014)

Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer
por: Popovici, Dorel, et al.
Publicado: (2021)

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis
por: Yu, Ke-Da, et al.
Publicado: (2013)

Long QT syndrome and torsade de pointes after anthracycline chemotherapy
por: Colombo, N, et al.
Publicado: (2009)

Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy
por: Blaes, Anne H, et al.
Publicado: (2015)

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
por: Beaudry, Rhys I., et al.
Publicado: (2019)

Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain
por: Costello, Benedict T., et al.
Publicado: (2019)

Use of 18F-FDG PET/CT Imaging for Radiotherapy Target Volume Delineation after Induction Chemotherapy and for Prognosis of Locally Advanced Squamous Cell Carcinoma of the Head and Neck
por: Rudžianskas, Viktoras, et al.
Publicado: (2018)

Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer – clinical evaluation of sensor-controlled scalp cooling
por: Friedrichs, Kay, et al.
Publicado: (2014)

Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent
por: Yu, Ke-Da, et al.
Publicado: (2016)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m777ldchsd82e81abcbj0ismma